BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.91, $0.38 better than the analyst estimate of $0.53. Revenue for the quarter came in at $746 million versus the consensus estimate of $703.14 million.

GUIDANCE:

BioMarin Pharma sees FY2024 EPS of $3.25-$3.35, versus the consensus of $3.22. BioMarin Pharma sees FY2024 revenue of $2.79-2.825 billion, versus the consensus of $2.799 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.